Rhythm Biosciences Ltd has released a press release.
COVID-19 Update
Filed with ASX ·
On 6ix: 6ix.com/news/covid-19-update-138
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Successful ISO13485 Surveillance Audit
- Rhythm Successfully Validates Key Biomarker
- Rhythm Biosciences Granted China Patent
- ColoSTAT - Test Development Update
- Appendix 4C
Later from Rhythm Biosciences
- Placement & Rights Offer to raise approximately $6 million
- Non-renounceable rights issue Offer
- Addtl Clinical Trial Site Signed - First Patient Recruited
- Revised CEO Contract and LTIP initiated for all employees
- Revised CEO Contract and LTIP for all employees - amended
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences